XenoPort accuses GSK of Horizant marketing breach; NICE gives final rejection to 3 cancer meds;

@FiercePharma: With pharma racing after rare diseases, the gov't has to step in to back antibiotics development--AP. Story | Follow @FiercePharma

> XenoPort has accused GlaxoSmithKline ($GSK) of breaching their marketing agreement on the restless legs syndrome drug Horizant by failing to maximize sales. Story

> The U.K.'s cost-effectiveness watchdogs gave a final rebuff to three colorectal cancer treatments: Merck KGaA's Erbitux, Roche's ($RHHBY) Avastin and Amgen's ($AMGN) Vectibix. News

> A Kaiser Permanente study found Merck's ($MRK) human papillomavirus vaccine Gardasil does not trigger autoimmune disorders. Release

> GlaxoSmithKline's health drink Horlicks outsells Pepsi two-to-one in India, and it's slated for a big emerging-markets push, a company executive says. Article

> Eli Lilly's ($LLY) animal health division Elanco agreed to buy the privately held food-enzyme maker ChemGen for an undisclosed sum. Report

> Biocon expects higher licensing revenues in its pharmaceuticals business after a year-over-year drop in fiscal third-quarter income in that area. Article

> South Korea's Hanmi inked a deal to supply 13 over-the-counter products to the Mongolian market in partnership with domestic pharma MEIC. News

> Jazz Pharmaceuticals shuffled its management team in the wake of its recently closed merger with Azur Pharma. Release

> CEO chair changes hands at Swiss pharma supplier Lonza, after 2011 profits drop by one-third. Report

Biotech News

@FierceBiotech: Roche's hostile Illumina bid highlights two hot trends in biopharma. News | Follow @FierceBiotech

@JohnCFierce: New research links children's exposure to PFCs--found all over the place--with lowered immune response to vaccines. Article | Follow @JohnCFierce

@MarkHFierce: Adult stem cells helped build a better rat penis. You read that right. More | Follow @MarkHFierce

> NEA turns to Europe in $30M round for RNA-drug developer Prosensa. News

> BioLineRx shares pop on hep C pact, raising temps in an overheated field. Story

> Lilly bows out of early-stage R&D joint venture with India's Jubilant. Article

Medical Device News

> Medtronic concludes enrollment in 'extreme risk' study of CoreValve. Item

> Roche looks to snatch up Illumina for $5.7B. More

Drug Delivery News

> Report: Roche transferring Israeli diabetes operations to Europe. Story

> Next-gen nanoparticles deliver cancer drugs at just the right moment. Article

> Mylan concocts ready-to-use epilepsy drug variation. News

> University of Arkansas heightens nanomedicine research efforts. Item

Biomarkers News

> Blood test could predict kidney disease 10 years early. Story

> Quintiles helps form personalized medicine joint venture. News

> Researchers fingerprint head, neck cancer for better diagnostics. Article

> Crosswords, reading cut Alzheimer's biomarker. More

And Finally... Cold-activated brown fat goes into calorie-burning overdrive when people get cold, researchers find. Story